Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by GameChangerBeton Jun 09, 2021 1:36pm
237 Views
Post# 33355906

RE:RE:RE:Anyone tuned into

RE:RE:RE:Anyone tuned intoI imagine they're refering to the list of 70 companies which include US and Europe pharmas, initial contact was said to be completed I believe a week or two ago, perhaps, or hopefully those conversations have accelerated into a possible deal in the near future.

On a side note, as per communication with Dan yesterday, there are no known events that will cause a delay to the start of Phase lll, they're ready to go.
I had a personal hunch that they wanted to start Phase lll only after a partnership was reached, but it will in fact be done in parallel to finding a partner.
So, as of yesterday, no known delays to the start of Phase lll, it will proceed as planned within the time stated.

CalgaryATE wrote:

 

MasterAlgae wrote: I have no sound. But the powerpoint is a year or more old - does not appear to be anything new...


If you watch it with sound, at the 5:08 mark Scott says:

"The large markets remained untapped.  These are the yellow stars you see on the map, those include the US, UK, EU4 and Japan.  We've now launched a large market partnering process and are also now entering confidential discussions for these markets." 

and at the 20:26 mark Scott says:

 

"And we've now kicked off our large market partnering outreach and confidential discussions have commenced."

I have no idea what consittutes a confidential discussion and where that would put them in the negotiating process, but at least they're having confidential discussions at this point of time.



<< Previous
Bullboard Posts
Next >>